{"entity":{"id":"nct00582166","kind":"trial","name":"Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance","aka":[],"tldr":"A phase 2 trial of Ibritumomab tiuxetan and Rituximab in Non-Hodgkin lymphoma, run by University of Wisconsin, Madison, recorded as terminated on the registry.","summary":"Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance is a phase 2 interventional study registered as NCT00582166 by University of Wisconsin, Madison, with 18 participants recorded, started 2005-01-25 and due to reach its primary completion in 2013-03. Interventions recorded: Ibritumomab Tiuxetan (Zevalin) + Rituximab. Conditions recorded: Non-Hodgkin's Lymphoma.\n\nLinked to the drug Ibritumomab tiuxetan because the registry names it among its interventions and Non-Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00582166","url":"https://clinicaltrials.gov/study/NCT00582166"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["ibritumomab-tiuxetan","rituximab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00582166","phase":"2","setting":"Ibritumomab Tiuxetan Plus Rituximab as Initial Therapy for Patients With High Tumor Burden, Indolent Histology Non-Hodgkin's Lymphoma","sponsor":"University of Wisconsin, Madison","enrolled":18,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00582166/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}]}}